Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, explains that clinical trials have adapted the use of biomarkers into the design of each study.
Trials are beginning to be designed not only to look at how a biomarker influences response but also its effect on overall survival and progression-free survival. Trials will be looking for biomarkers that not only predict a response but also show an improvement in survival.
Tripathy explains it is becoming uncommon to see a trial that is not containing a biomarker investigation.
Ещё видео!